Osimertinib Mesylate
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for Osimertinib Mesylate, covering 2022-03-17 to 2025-04-08. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs [Phase 3]